GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
出版年份 2018 全文链接
标题
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
作者
关键词
Cardiovascular outcomes, Diabetes, GLP-1 receptor agonist, Obesity
出版物
Cardiovascular Diabetology
Volume 17, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-12-13
DOI
10.1186/s12933-018-0800-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors
- (2018) Vladimer Darsalia et al. Cardiovascular Diabetology
- Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials
- (2018) Atsushi Tanaka et al. Cardiovascular Diabetology
- Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
- (2018) Tina Vilsbøll et al. DIABETES OBESITY & METABOLISM
- Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
- (2018) Sean L. Zheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
- (2018) Edison Goncalves et al. Diabetes Therapy
- Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
- (2018) Edison Goncalves et al. Diabetes Therapy
- Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
- (2018) Anne Kugler et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
- (2018) Stephen C. Bain et al. DIABETES OBESITY & METABOLISM
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species
- (2017) Lene Jensen et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- The safety of albiglutide for the treatment of type 2 diabetes
- (2017) Marc S. Rendell Expert Opinion On Drug Safety
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes
- (2017) Rebecca L. Scalzo et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
- (2017) Aidin Rawshani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Population pharmacokinetics of exenatide
- (2016) Brenda Cirincione et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study
- (2016) Preman Kumarathurai et al. Cardiovascular Diabetology
- Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study
- (2016) Manfredi Rizzo et al. Cardiovascular Diabetology
- Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
- (2016) Keith C. Ferdinand et al. Cardiovascular Diabetology
- Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis
- (2016) Michael A. Gimbrone et al. CIRCULATION RESEARCH
- Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes
- (2016) Manasi S. Shah et al. CIRCULATION RESEARCH
- Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis
- (2016) Alison Cameron-Vendrig et al. DIABETES
- Glucagon-Like Peptide 1 Receptor Activation and Platelet Function: Beyond Glycemic Control
- (2016) Guanghong Jia et al. DIABETES
- Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study
- (2016) Preman Kumarathurai et al. DIABETES CARE
- Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
- (2016) Michael Nauck et al. DIABETES CARE
- Hypoglycemia and Cardiovascular Risk: Is There a Major Link?
- (2016) Markolf Hanefeld et al. DIABETES CARE
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
- (2016) Kenneth B. Margulies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Targeting the gastrointestinal tract to treat type 2 diabetes
- (2016) Paige V Bauer et al. JOURNAL OF ENDOCRINOLOGY
- The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia
- (2016) Fangzhe Chen et al. Journal of Neuroinflammation
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction
- (2016) John J. Lepore et al. JACC-Heart Failure
- Mechanisms for the cardiovascular effects of glucagon-like peptide-1
- (2015) H. Poudyal Acta Physiologica
- Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
- (2015) Wei Ren Chen et al. AMERICAN HEART JOURNAL
- Flow-mediated dilation: An evolving method
- (2015) Thiago Quinaglia et al. ATHEROSCLEROSIS
- Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans
- (2015) Juraj Koska et al. DIABETES
- Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
- (2015) Sten Madsbad DIABETES OBESITY & METABOLISM
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Glucagon-Like Receptor 1 Agonists and DPP-4 Inhibitors: Potential Therapies for the Treatment of Stroke
- (2015) Vladimer Darsalia et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and obesity: a review of the data so far
- (2015) Ellen Ladenheim Drug Design Development and Therapy
- The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
- (2015) Jessica E. Potts et al. PLoS One
- Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
- (2014) Francisco Kerr Saraiva et al. Cardiovascular Diabetology
- Incretin Therapy and Heart Failure
- (2014) Jun-ichi Oyama et al. CIRCULATION JOURNAL
- HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea
- (2014) Peter N. Weissman et al. DIABETOLOGIA
- The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
- (2014) Mikkel Christensen et al. Expert Opinion on Drug Discovery
- Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
- (2014) Maria Voukali et al. Journal of Diabetes Research
- Endothelial dysfunction — A major mediator of diabetic vascular disease
- (2013) Cristina M. Sena et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
- (2013) Lesley J. Scott BIODRUGS
- Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation
- (2013) K Pabreja et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model
- (2013) Tracey Gaspari et al. Diabetes & Vascular Disease Research
- Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
- (2013) B. Wang et al. DIABETES OBESITY & METABOLISM
- Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients
- (2013) N. D. Hopkins et al. DIABETES OBESITY & METABOLISM
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2013) EUROPEAN HEART JOURNAL
- Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I
- (2013) Francesco Paneni et al. EUROPEAN HEART JOURNAL
- Neuroprotective Effects of Liraglutide for Stroke Model of Rats
- (2013) Kenichiro Sato et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
- (2013) Steven E Kahn et al. LANCET
- Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study)
- (2013) Priscilla Hollander et al. Obesity
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
- (2012) Kerry Hunter et al. BMC NEUROSCIENCE
- GLP-1 and cardioprotection: from bench to bedside
- (2012) S. Ravassa et al. CARDIOVASCULAR RESEARCH
- Postprandial dyslipidaemia and diabetes
- (2012) Jing Pang et al. CURRENT OPINION IN LIPIDOLOGY
- Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research
- (2012) Concetta Irace et al. Diabetes & Vascular Disease Research
- The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
- (2012) J. Rosenstock et al. DIABETES CARE
- Standards of Medical Care in Diabetes--2013
- (2012) DIABETES CARE
- Cellular Dysfunction in Diabetes as Maladaptive Response to Mitochondrial Oxidative Stress
- (2012) Alba Naudi et al. Experimental Diabetes Research
- Liraglutide, a Long-Acting GLP-1 Mimetic, and its Metabolite Attenuate Inflammation after Intracerebral Hemorrhage
- (2012) Jack Hou et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- GLP1-derived nonapeptide GLP1(28–36)amide protects pancreatic β-cells from glucolipotoxicity
- (2012) Zhengu Liu et al. JOURNAL OF ENDOCRINOLOGY
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Postprandial Dysmetabolism and the Heart
- (2012) Alan J. Garber Heart Failure Clinics
- Preventive Effects of Exenatide on Endothelial Dysfunction Induced by Ischemia-Reperfusion Injury via K ATP Channels
- (2011) Sang Jin Ha et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model
- (2011) Tracey Gaspari et al. Diabetes & Vascular Disease Research
- The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study
- (2011) G. E. Umpierrez et al. DIABETES OBESITY & METABOLISM
- Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care
- (2011) M. K. Rutter et al. EUROPEAN HEART JOURNAL
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
- (2011) Jacob Lønborg et al. EUROPEAN HEART JOURNAL
- GLP-1-derived nonapeptide GLP-1(28–36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes
- (2011) Eva Tomas et al. REGULATORY PEPTIDES
- Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus
- (2010) Eric A. Schwartz et al. ATHEROSCLEROSIS
- Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database
- (2010) J. H. Best et al. DIABETES CARE
- Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase
- (2010) M. Malm-Erjefalt et al. DRUG METABOLISM AND DISPOSITION
- Taspoglutide, an Analog of Human Glucagon-Like Peptide-1 with Enhanced Stability andin VivoPotency
- (2010) Elena Sebokova et al. ENDOCRINOLOGY
- Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor
- (2010) Kiwon Ban et al. ENDOCRINOLOGY
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
- (2009) Lisbeth V. Jacobsen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Incretin-Based Therapies: Viewpoints on the way to consensus
- (2009) Michael. A. Nauck et al. DIABETES CARE
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
- (2009) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis
- (2009) Eva Tomas et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP
- (2008) Brian D. Green et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects
- (2008) Susanne Lerche et al. CLINICAL ENDOCRINOLOGY
- Efficient mitochondrial targeting relies on co-operation of multiple protein signals in plants
- (2008) Laurent Chatre et al. JOURNAL OF EXPERIMENTAL BOTANY
- Diabetes and atherosclerosis: is there a role for hyperglycemia?
- (2008) Alan Chait et al. JOURNAL OF LIPID RESEARCH
- Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Paget's Disease of the Mandible
- (2008) Mayank B. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart
- (2007) David P. Sonne et al. REGULATORY PEPTIDES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started